Daphne A Haas-Kogan

List of Publications by Year
in descending order

125 papers	5,499 citations	126907 33 h-index	88630 70 g-index
128 all docs	128 docs citations	128 times ranked	8277 citing authors

#	Article	IF	Citations
1	Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study. Journal of Clinical Oncology, 2009, 27, 1007-1013.	1.6	768
2	Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro-Oncology, 2017, 19, 1511-1521.	1.2	483
3	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	27.8	374
4	Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 999-1008.	10.7	246
5	Brain Metastases in Newly Diagnosed Breast Cancer. JAMA Oncology, 2017, 3, 1069.	7.1	224
6	Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma. JAMA - Journal of the American Medical Association, 2019, 322, 746.	7.4	220
7	Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-Oncology, 2017, 19, now101.	1.2	217
8	Artificial intelligence in radiation oncology. Nature Reviews Clinical Oncology, 2020, 17, 771-781.	27.6	167
9	Impact of radiotherapy for high-risk neuroblastoma: a Childrenâ€™s Cancer Group study. International Journal of Radiation Oncology Biology Physics, 2003, 56, 28-39.	0.8	149
10	A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Cancer Cell, 2017, 31, 424-435.	16.8	138
11	National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. International Journal of Radiation Oncology Biology Physics, 2018, 101, 152-168.	0.8	138
12	Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro-Oncology, 2014, 16, 352-360.	1.2	102
13	Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. Journal of Clinical Oncology, 2017, 35, 208-216.	1.6	100
14	Management of pediatric low-grade glioma. Current Opinion in Pediatrics, 2019, 31, 21-27.	2.0	87
15	The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. Nature Communications, 2019, 10, 442.	12.8	86
16	PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro-Oncology, 2012, 14, 1146-1152.	1.2	85
17	Therapeutic radiation and the potential risk of second malignancies. Cancer, 2016, 122, 1809-1821.	4.1	85
18	The Future of Radiobiology. Journal of the National Cancer Institute, 2018, 110, 329-340.	6.3	76

#	Article	IF	Citations
19	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	1.2	73
20	Biomarkers to Predict Response to Epidermal Growth Factor Receptor Inhibitors. Cell Cycle, 2005, 4, 1369-1372.	2.6	69
21	Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms. Cancer Letters, 2011, 306, 223-229.	7.2	66
22	Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. Future Oncology, 2013, 9, 219-233.	2.4	62
23	Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clinical Cancer Research, 2015, 21, 2715-2721.	7.0	62
24	Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma In Vitro and In Vivo Model Systems. Clinical Cancer Research, 2011, 17, 2339-2349.	7.0	61
25	Dual HDAC and PI3K Inhibition Abrogates NFÎºB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Research, 2018, 78, 4007-4021.	0.9	60
26	Radiation-induced gliomas. Expert Review of Neurotherapeutics, 2009, 9, 1511-1517.	2.8	52
27	Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro-Oncology, 2017, 19, 78-88.	1.2	51
28	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro-Oncology, 2021, 23, 1872-1884.	1.2	48
29	Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. Journal of Neuro-Oncology, 2016, 126, 193-200.	2.9	45
30	Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nature Communications, 2019, 10, 3731.	12.8	45
31	Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. Journal of Neuro-Oncology, 2018, 140, 629-638.	2.9	44
32	Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clinical Cancer Research, 2020, 26, 1213-1219.	7.0	38
33	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Journal of Clinical Oncology, 2021, 39, 3506-3514.	1.6	38
34	Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. Oncotarget, 2017, 8, 84697-84713.	1.8	38
35	Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Childrenâ€™s Oncology Group ANBL0532 Study. Journal of Clinical Oncology, 2020, 38, 2741-2752.	1.6	36
36	The Children's Oncology Group Radiation Oncology Discipline: 15ÂYears of Contributions to the Treatment of Childhood Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 860-874.	0.8	34

#	Article	IF	Citations
37	Long-term side effects of radiotherapy for pediatric localized neuroblastoma. Strahlentherapie Und Onkologie, 2015, 191, 604-612.	2.0	32
38	The Combination of Novel Targeted Molecular Agents and Radiation in the Treatment of Pediatric Gliomas. Frontiers in Oncology, 2013, 3, 110.	2.8	31
39	Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Journal of Neuro-Oncology, 2016, 126, 385-393.	2.9	31
40	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood and Cancer, 2018, 65, e27023.	1.5	31
41	Prostate Cancer Screening Patterns Among Sexual and Gender Minority Individuals. European Urology, 2021, 79, 588-592.	1.9	31
42	Clinical Impact of Tumor Mutational Burden in Neuroblastoma. Journal of the National Cancer Institute, 2019, 111, 695-699.	6.3	29
43	A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 726-735.	0.8	29
44	Large Vessel Arteriopathy After Cranial Radiation Therapy in Pediatric Brain Tumor Survivors. Journal of Child Neurology, 2018, 33, 359-366.	1.4	27
45	Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. Neuro-Oncology, 2020, 22, 1339-1347.	1.2	27
46	Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Childrenâ€™s Oncology Group Trials. JAMA Oncology, 2020, 6, 1465.	7.1	26
47	Population-based estimates of survival among elderly patients with brain metastases. Neuro-Oncology, 2021, 23, 661-676.	1.2	25
48	Clinical Characteristics, Experiences, and Outcomes of Transgender Patients With Cancer. JAMA Oncology, 2021, 7, e205671.	7.1	23
49	Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma. Molecular Cancer Therapeutics, 2018, 17, 347-354.	4.1	22
50	Revisiting the Role of Radiation Therapy for Pediatric Low-Grade Glioma. Journal of Clinical Oncology, 2019, 37, 3335-3339.	1.6	21
51	Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. International Journal of Radiation Oncology Biology Physics, 2017, 97, 270-277.	0.8	20
52	Cooperative Blockade of PKCÎ± and JAK2 Drives Apoptosis in Glioblastoma. Cancer Research, 2020, 80, 709-718.	0.9	19
53	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for nonâ€“small cell lung cancer and melanoma brain metastases. Cancer, 2020, 126, 5274-5282.	4.1	19
54	Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas. Future Oncology, 2016, 12, 1493-1506.	2.4	18

#	Article	IF	Citations
55	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiotherapy and Oncology, 2018, 126, 511-518.	0.6	18
56	Risk stratification by somatic mutation burden in Ewing sarcoma. Cancer, 2019, 125, 1357-1364.	4.1	18
57	Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. World Neurosurgery, 2019, 122, e1557-e1561.	1.3	17
58	Brainstem Injury in Pediatric Patients Receiving Posterior Fossa Photon Radiation. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1034-1042.	0.8	16
59	Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. Breast Cancer Research and Treatment, 2019, 176, 171-179.	2.5	15
60	Breast and Cervical Cancer Screening Disparities in Transgender People. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 116-121.	1.3	14
61	Medical Student Perspectives on a Multi-institutional Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 217-219.	0.8	13
62	Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients. Journal of Neuro-Oncology, 2017, 131, 359-368.	2.9	13
63	Local control after brain-directed radiation in patients with cystic versus solid brain metastases. Journal of Neuro-Oncology, 2019, 142, 355-363.	2.9	13
64	Blood-brain barrierâ€“adapted precision medicine therapy for pediatric brain tumors. Translational Research, 2017, 188, 27.e1-27.e14.	5.0	12
65	Utility of claims data for identification of date of diagnosis of brain metastases. Neuro-Oncology, 2020, 22, 575-576.	1.2	12
66	Seizures Among Patients With Brain Metastases. Neurology, 2021, 96, .	1.1	12
67	Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. Neuro-Oncology Practice, 2020, 7, 4-10.	1.6	11
68	Practice patterns and recommendations for pediatric imageâ€guided radiotherapy: A Children's Oncology Group report. Pediatric Blood and Cancer, 2020, 67, e28629.	1.5	11
69	Harnessing Lactate Metabolism for Radiosensitization. Frontiers in Oncology, 2021, 11, 672339.	2.8	11
70	A Cautionary Tale: Risks of Radiation Therapy De-Escalation in Pediatric Malignancies. Journal of Clinical Oncology, 2017, 35, 2471-2472.	1.6	8
71	Role of the extent of prophylactic regional lymph node radiotherapy on survival in highâ€risk neuroblastoma: A report from the COG A3973 study. Pediatric Blood and Cancer, 2019, 66, e27736.	1.5	8
72	Reirradiation practices for children with diffuse intrinsic pontine glioma. Neuro-Oncology Practice, 2021, 8, 68-74.	1.6	8

#	Article	IF	Citations
73	Standardization and Quality Assurance of Radiation Therapy Volumes for Adults With High-Grade Gliomas. Seminars in Radiation Oncology, 2014, 24, 259-264.	2.2	7
74	Towards a standard of care in oncology for transgender patients. Lancet Oncology, The, 2019, 20, 331-333.	10.7	7
75	Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study. Journal of Neuro-Oncology, 2020, 148, 509-517.	2.9	7
76	Hospice Utilization in Elderly Patients With Brain Metastases. Journal of the National Cancer Institute, 2020, 112, 1251-1258.	6.3	7
77	CTNI-19. PHASE I TRIAL OF DAY101 IN PEDIATRIC PATIENTS WITH RADIOGRAPHICALLY RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA (LGG). Neuro-Oncology, 2020, 22, ii46-ii46.	1.2	7
78	A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors. International Journal of Radiation Oncology Biology Physics, 2022, 113, 143-151.	0.8	7
79	Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131 I-Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, 468-475.	0.8	6
80	Treating the SARSâ€CoVâ€2â€“positive patient with cancer: A proposal for a pragmatic and transparent ethical process. Cancer, 2020, 126, 3896-3899.	4.1	5
81	Gliomas, germ cell tumors, and craniopharyngioma. Pediatric Blood and Cancer, 2021, 68, e28401.	1.5	5
82	Update on Radiation Therapy for Central Nervous System Tumors. Hematology/Oncology Clinics of North America, 2022, 36, 77-93.	2.2	5
83	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. Neuro-Oncology, 2020, 22, ii44-ii44.	1.2	5
84	Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: Single-institution prospective study at University of California, San Francisco. Practical Radiation Oncology, 2015, 5, e45-e51.	2.1	4
85	Feasibility of hippocampal avoidance whole brain radiation in patients with hippocampal involvement: Data from a prospective study. Medical Dosimetry, 2021, 46, 21-28.	0.9	4
86	Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-<scp>l</scp>-glutamic Acidâ€“coated Layer-by-Layer Nanoparticles. Molecular Cancer Therapeutics, 2021, 20, 726-738.	4.1	4
87	Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. JAMA Network Open, 2021, 4, e213304.	5.9	4
88	Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures. Radiation Research, 2021, 197, .	1.5	4
89	EPCT-01. PHASE I STUDY OF DAY101 (TAK580) IN CHILDREN AND YOUNG ADULTS WITH RADIOGRAPHICALLY RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA (LGG). Neuro-Oncology, 2020, 22, iii304-iii304.	1.2	4
90	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. Neuro-Oncology, 2020, 22, ii43-ii44.	1.2	3

#	Article	IF	Citations
91	Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. Journal of Pediatric Hematology/Oncology, 2020, 42, e647-e654.	0.6	2
92	Utility of claims data for delineation of intracranial treatment among patients with brain metastases. Neuro-Oncology, 2020, 22, 1547-1548.	1.2	2
93	What HIV/AIDS Taught Me About Pandemics: A Clinicianâ€™s Perspective. International Journal of Radiation Oncology Biology Physics, 2020, 108, 346-347.	0.8	2
94	PATH-12. TEMOZOLOMIDE-INDUCED HYPERMUTATION IS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION, DISTANT RECURRENCE AND REDUCED SURVIVAL IN INITIALLY LOW GRADE IDH-MUTANT GLIOMAS. Neuro-Oncology, 2020, 22, ii166-ii166.	1.2	2
95	Patient specific distortion detection and mitigation in MR images used for stereotactic radiosurgery. Physics in Medicine and Biology, 2022, 67, 065009.	3.0	2
96	Predictors of long-term survival among patients with brain metastases. Neuro-Oncology, 2022, , .	1.2	2
97	Trends in location of death for individuals with primary brain tumors in the United States. Neuro-Oncology, 2022, 24, 1400-1401.	1.2	2
98	DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. Journal of Neuro-Oncology, 2022, 157, 499-510.	2.9	2
99	Gender, Productivity, and Philanthropic Fundraising in Academic Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1401-1406.	4.9	2
100	Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Childrenâ€™s Oncology Group phase I consortium study. Neuro-Oncology Advances, 2022, 4, .	0.7	2
101	Non-Muscle Myosin IIa Heavy Chain Links Squamous-Cell Carcinoma of the Head and Neck to the DNA Damage Response. Frontiers in Oncology, 2014, 4, 228.	2.8	1
102	Reply to J. Stenman et al. Journal of Clinical Oncology, 2017, 35, 1966-1967.	1.6	1
103	Longâ€term outcomes of pediatric and young adult patients receiving radiotherapy for nonmalignant vascular anomalies. Pediatric Blood and Cancer, 2021, 68, e28955.	1.5	1
104	Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis. Neuro-Oncology Practice, 2021, 8, 569-580.	1.6	1
105	Clinical outcomes for pediatric patients receiving radiotherapy for solid tumor central nervous system metastases. Pediatric Blood and Cancer, 2021, 68, e29331.	1.5	1
106	Anatomic patterns of relapse and progression following treatment with 131 Iâ€MIBG in relapsed or refractory neuroblastoma. Pediatric Blood and Cancer, 2021, , e29396.	1.5	1
107	Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: a population- and institutional-level analysis. Neuro-Oncology Practice, 2022, 9, 114-122.	1.6	1
108	DDRE-12. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG). Neuro-Oncology, 2020, 22, ii63-ii64.	1.2	1

#	Article	IF	Citations
109	Toward an Improved Understanding of the Ionizing Radiation Induced DNA Damage/Response Networks in Human Malignancies. Frontiers in Oncology, 2014, 4, 335.	2.8	0
110	Preface. Seminars in Radiation Oncology, 2014, 24, 233-234.	2.2	0
111	In Reply to Bull etÂal. International Journal of Radiation Oncology Biology Physics, 2014, 89, 434.	0.8	0
112	PNR-17HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANT TO DELAY RADIATION IN PEDIATRIC EMBRYONAL BRAIN TUMOR PATIENTS. Neuro-Oncology, 2016, 18, iii10.1-iii10.	1.2	0
113	ACTR-32. AÂPROSPECTIVE PHASE II STUDY OF EVEROLIMUS FOR RECURRENT ADULT LOW GRADE GLIOMAS. Neuro-Oncology, 2016, 18, vi8-vi9.	1.2	0
114	HGG-36. NFÎºB AND FOXM1 MEDIATE ANTI-CANCER ACTIVITY OF DUAL HDAC AND PI3K INHIBITION IN PEDIATRIC HIGH GRADE GLIOMA AND DIPG. Neuro-Oncology, 2018, 20, i96-i97.	1.2	0
115	A Central Role of Radiation Therapy in Central Nervous System Germinoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 970-971.	0.8	0
116	THER-34. MEK BLOCKADE SYNERGISTICALLY INCREASES THE ANTI-TUMOR EFFECTS OF mTOR INHIBITION IN GLIOMAS. Neuro-Oncology, 2019, 21, ii121-ii121.	1.2	0
117	DIPG-12. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs). Neuro-Oncology, 2019, 21, ii70-ii71.	1.2	0
118	DIPG-24. DIFFUSE INTRINSIC PONTINE GLIOMAS EXHIBIT HIGH BASAL DNA DAMAGE AND ARE VULNERABLE TO INHIBITION OF DNA DAMAGE REPAIR PATHWAYS. Neuro-Oncology, 2019, 21, ii73-ii74.	1.2	0
119	DDRE-32. THERAPEUTIC TARGETING OF A NOVEL METABOLIC ADDICTION IN DIFFUSE MIDLINE GLIOMA. Neuro-Oncology Advances, 2021, 3, i13-i13.	0.7	0
120	HGG-38. DE NOVO PYRIMIDINE SYNTHESIS INHIBITION INDUCES REPLICATION CATASTROPHE MEDIATED CELL DEATH IN DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 2021, 23, i25-i25.	1.2	0
121	GCT-33. A PHASE 2 TRIAL OF RESPONSE-BASED RADIATION THERAPY FOR PATIENTS WITH LOCALIZED CENTRAL NERVOUS SYSTEM GERM CELL TUMORS: A CHILDRENâ€™S ONCOLOGY GROUP (COG) STUDY. IMPACT OF RAPID CENTRAL RADIOTHERAPY REVIEW ON RADIOTHERAPY QUALITY AND PATTERN OF FAILURE FOR NON-GERMINOMATOUS GERM CELL TUMORS. Neuro-Oncology, 2020, 22, iii334-iii334.	1.2	0
122	DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS). Neuro-Oncology, 2020, 22, iii297-iii297.	1.2	0
123	DIPG-01. REIRRADIATION PRACTICES FOR DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2020, 22, iii287-iii287.	1.2	0
124	â€œPer protocolâ€•practice patterns for Children's Oncology Group trials within the radiation oncology community. Pediatric Blood and Cancer, 2022, , e29673.	1.5	0
125	LGG-52. Volumetry-based response characterization of recurrent pediatric low-grade gliomas in PNOC clinical Neuro-oncology trials. Neuro-Oncology, 2022, 24, i100-i100.	1.2	0